Kamada (KMDA) EBIT Margin (2012 - 2026)
Kamada's (KMDA) quarterly EBIT Margin came in at 17.32% in Q2 2026, up 152.0% on a YoY basis from 6.87% in Q2 2025, and up 12.67% quarter-over-quarter from 15.37% in Q1 2026.
Powered by 
Analysis
Kamada (KMDA) EBIT Margin (2012 - 2026) Analysis & Trends
Kamada (KMDA) has reported EBIT Margin for 15 consecutive years, with 17.32% the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, EBIT Margin rose 152.0% year-over-year to 17.32%; the trailing twelve-month figure through Jun 2026 stood at 14.51% (down 38.0% YoY), and the FY2025 full-year result was 14.54%, up 208.0% from the prior year.
- EBIT Margin advanced to 17.32% in Q2 2026 per KMDA's latest filing, from 15.37% in the prior quarter.
- Across five years, EBIT Margin topped out at 17.71% in Q1 2025 and bottomed at 9.72% in Q2 2022.
- Historically, EBIT Margin has averaged 9.75% across 5 years, with a median of 11.11% in 2024.
- The widest YoY moves for EBIT Margin: up 1934 bps in 2022, down 1404 bps in 2022.
- Over 5 years, EBIT Margin stood at 8.84% in 2022, then dropped by 14 bps to 7.62% in 2023, then surged by 71 bps to 13.02% in 2024, then slumped by 39 bps to 7.95% in 2025, then jumped by 118 bps to 17.32% in 2026.
- According to Business Quant data, EBIT Margin over the past three periods registered 17.32%, 15.37%, and 7.95% for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.30 Bn | 197.31 Bn | 7.24 Bn | 34.95% |
| 2 | Gilead Sciences | 180.97 Bn | 177.79 Bn | 6.22 Bn | -133.21% |
| 3 | Vertex Pharmaceuticals | 132.27 Bn | 124.42 Bn | 2.84 Bn | 37.40% |
| 4 | Regeneron Pharmaceuticals | 82.93 Bn | 74.93 Bn | 3.93 Bn | 30.15% |
| 5 | Argenx Se | 61.53 Bn | 56.35 Bn | 1.37 Bn | 32.54% |
| 6 | Moderna | 54.27 Bn | 49.13 Bn | 52.00 Mn | -562.07% |
| 7 | Alnylam Pharmaceuticals | 34.46 Bn | 31.15 Bn | 992.69 Mn | 17.93% |
| 8 | Biogen | 31.16 Bn | 29.88 Bn | 1.96 Bn | -23.56% |
| 9 | Roivant Sciences | 30.08 Bn | 30.08 Bn | 1.16 Mn | -25,380.93% |
| 10 | Kamada | 473.85 Mn | 403.72 Mn | 22.47 Mn | 17.32% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 17.32% |
| Mar 31, 2026 | 15.37% |
| Dec 31, 2025 | 7.95% |
| Sep 30, 2025 | 16.63% |
| Jun 30, 2025 | 15.80% |
| Mar 31, 2025 | 17.71% |
| Dec 31, 2024 | 13.02% |
| Sep 30, 2024 | 12.68% |
| Jun 30, 2024 | 13.28% |
| Mar 31, 2024 | 10.70% |
| Dec 31, 2023 | 7.62% |
| Sep 30, 2023 | 11.51% |
| Jun 30, 2023 | 7.03% |
| Mar 31, 2023 | 0.94% |
| Dec 31, 2022 | 8.84% |
| Sep 30, 2022 | 7.95% |
| Jun 30, 2022 | -9.72% |
| Mar 31, 2022 | 0.88% |
| Dec 31, 2021 | -10.49% |
| Sep 30, 2021 | -3.49% |